Sabcomeline
Alternative Names: BCI-224; CEB 242; Memric; SB-202026Latest Information Update: 23 Jul 2015
At a glance
- Originator GlaxoSmithKline
- Developer BrainCells; GlaxoSmithKline
- Class Antidepressants; Imines; Quinuclidines; Small molecules
- Mechanism of Action Muscarinic M1 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Alzheimer's disease; Cognition disorders; Major depressive disorder; Schizophrenia; Type 2 diabetes mellitus
Most Recent Events
- 14 Aug 2012 Proximagen has been acquired by Upsher-Smith
- 26 Jun 2012 Sabcomeline is available for licensing as of 26 Jun 2012. http://www.braincellsinc.com
- 19 Apr 2011 Phase-I clinical development in Cognition disorders in USA (unspecified route)